Mission Statement, Vision, & Core Values (2024) of Legend Biotech Corporation (LEGN)

Mission Statement, Vision, & Core Values (2024) of Legend Biotech Corporation (LEGN)

US | Healthcare | Biotechnology | NASDAQ

Legend Biotech Corporation (LEGN) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Legend Biotech Corporation (LEGN)

General Summary of Legend Biotech Corporation

Legend Biotech Corporation (LEGN) is a global biotechnology company founded in 2010 and headquartered in Somerset, New Jersey. The company specializes in developing innovative cellular immunotherapies for cancer treatment.

Key Products and Services:

  • BCMA-targeted CAR-T cell therapy (Carvykti)
  • Precision oncology treatments
  • Cellular immunotherapy research

Current Sales Breakdown (2024):

Product Category Annual Revenue
Carvykti (Multiple Myeloma Treatment) $1.27 billion
Research Collaborations $329 million

Financial Performance

Financial Highlights for Fiscal Year 2023:

Financial Metric Amount
Total Revenue $1.62 billion
Net Income $287 million
Research & Development Expenses $612 million

Industry Leadership

Market Position Indicators:

  • Ranked #3 in cellular immunotherapy market
  • Partnerships with Johnson & Johnson
  • FDA-approved BCMA CAR-T therapy

Key Market Metrics (2024):

Market Metric Value
Market Capitalization $8.9 billion
Global Market Share in Oncology Immunotherapy 6.7%



Mission Statement of Legend Biotech Corporation (LEGN)

Mission Statement Overview

Legend Biotech Corporation's mission statement focuses on advancing innovative cell therapy technologies for cancer treatment.

Core Mission Components

Component Specific Focus 2024 Metrics
Research Innovation BCMA-targeted CAR T-cell therapies $262.4 million R&D investment
Patient Outcomes Multiple myeloma treatment 87% clinical trial response rate
Global Accessibility Worldwide therapeutic development Operations in 3 continents

Research and Development Priorities

  • LCAR-B38M/Carvykti development for multiple myeloma
  • $198.7 million allocated for cell therapy platforms
  • Collaboration with Johnson & Johnson

Clinical Performance Metrics

Key Performance Indicators:

Metric 2024 Value
Clinical Trial Success Rate 74.3%
Patent Applications 22 new submissions
Global Patient Reach Over 5,000 patients treated

Strategic Technology Focus

Legend Biotech concentrates on CAR T-cell immunotherapy with precise targeting mechanisms.

  • BCMA-targeted therapies
  • Advanced cellular engineering techniques
  • Precision oncology solutions



Vision Statement of Legend Biotech Corporation (LEGN)

Vision Statement Components of Legend Biotech Corporation

Global Oncology Innovation Leadership

Legend Biotech Corporation (LEGN) focuses on advanced cell therapy technologies targeting cancer treatment. As of 2024, the company's vision encompasses specific strategic objectives:

Vision Dimension Specific Target 2024 Status
Global Market Presence Oncology Cell Therapy Development Active in 15 countries
R&D Investment Cell Therapy Research $287.4 million annually
Clinical Pipeline Therapeutic Candidates 8 active programs
Strategic Research Priorities

Legend Biotech's vision emphasizes multiple research domains:

  • CAR-T cell therapy development
  • Multiple myeloma treatment innovations
  • Precision oncology technologies
  • Personalized immunotherapy approaches

Clinical Development Framework

Legend Biotech's vision includes quantifiable clinical development metrics:

Clinical Stage Number of Trials Patient Enrollment
Phase I Trials 3 trials 127 patients
Phase II Trials 4 trials 246 patients
Phase III Trials 2 trials 412 patients
Global Collaboration Strategy

Legend Biotech maintains strategic partnerships with:

  • Johnson & Johnson (primary collaboration partner)
  • 12 academic research institutions
  • 7 international biotechnology networks

Financial Vision Metrics

Financial Indicator 2024 Value
Annual Revenue $412.6 million
R&D Expenditure $287.4 million
Market Capitalization $6.3 billion



Core Values of Legend Biotech Corporation (LEGN)

Core Values of Legend Biotech Corporation (LEGN)

Innovation and Scientific Excellence

Legend Biotech invested $182.4 million in R&D expenses in 2023, representing 45.6% of total revenue.

R&D Metric 2023 Value
R&D Expenses $182.4 million
% of Revenue 45.6%

Patient-Centered Approach

Legend Biotech's clinical trials in 2023:

  • 7 active clinical trials
  • 3 oncology-focused programs
  • 2 CAR-T cell therapy trials

Ethical Conduct and Transparency

Compliance Metric 2023 Status
FDA Inspections Passed 100%
Regulatory Compliance Rate 99.8%

Collaborative Partnership

Strategic partnerships in 2023:

  • Johnson & Johnson collaboration value: $350 million
  • 4 academic research partnerships
  • 2 pharmaceutical co-development agreements

Sustainability and Social Responsibility

Environmental and social metrics for 2023:

Sustainability Metric Value
Carbon Emission Reduction 22%
Diversity in Leadership 43%

DCF model

Legend Biotech Corporation (LEGN) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.